- Only 13.8% of all biopharma drug lines on average are ever approved – wasting a whopping 86.2% of total R&D investment.
- The traditional drug pricing model is under a bipartisan political and economic attack that will last far beyond 2020.
- Biopharma companies like yours have recovered $750,000+ in operating costs to fund R&D and other priorities through active asset management and valuation strategies.
Find New Funds for
Biopharmaceutical
Research and Development
– or any of your company’s current priorities through asset management and valuation.
New market research analysis reveals:
Download the full white paper for free –
Just fill out the form, and we’ll send it straight to you.
Just fill out the form, and we’ll send it straight to you.